The high-throughput model aims to accelerate drug development
Biotechnology company Creative Bioarray has launched high-throughput ADME screening services to help researchers identify lead candidates with favourable ADME profiles more quickly.
"Our high-throughput ADME screening services not only improve the efficiency of the drug development process but also provide clients with precise and actionable insights into compound pharmacokinetic properties,” said Creative Bioarray marketing director Hannah Cole.
The company’s screening service combines an automated intelligent experimental platform with advanced bioinformatics analysis tools.
The tool generates datasets to support scientific decision-making in drug development. The aim is to achieve faster advancements in biologics-based therapies.
Automated screening ensures high accuracy and reproducibility across large sample sizes, reducing data acquisition time. Advanced bioinformatics tools provide in-depth analysis, helping researchers to understand the behaviour of their compounds in biological systems.
